The primary objective of the Hawaii Minority-Based Community Clinical Oncology (MBCCOP) is to build on its past 15 year success in providing National Cancer Institute (NCI) clinical trials to Hawaii cancer patients and high risk individuals in order to reduce cancer incidence, morbidity and mortality by: 1. providing support to expand clinical research in the State of Hawaii, a multiethnic population with a majority of ethnic minority patients;2. bringing the advantages of state-of-the-science treatment and prevention/control research to minority individuals in their own communities;3. facilitating broader participation among underserved populations in NCI-approved research;4. strengthening the operational base that presently exists to extend cancer prevention and control research in the population;5. increasing the involvement of primary health care providers and other specialists in cancer treatment, prevention, and control studies. The Cancer Research Center of Hawaii will serve as the administrative headquarters for the MBCCOP and will direct recruitment, accrual, and data management for NCI-approved cancer treatment, prevention and symptom control clinical trials. Sources of clinical trials include: SWOG, GOG, COG, RTOG, URCC, CTSU, and NSABP prevention trials. Participating physicians include oncologists on Oahu, Kauai, Maui, and the Big Island of Hawaii as well as professionals from other medical and non-medical specialties. All major hospitals in the state will serve as component/affiliate institutions. The MBCCOP will allow the people of Hawaii, about 75% who are ethnic minorities, to benefit from access to state-of-the-science cancer treatment, prevention and symptom control studies while providing valuable clinical research data on a unique population.
Provide access to NCI-approved cancer treatment, prevention and control clinical trials for the people of Hawaii especially for minorities and under-served populations. Lower the burden of cancer in the State of Hawaii. Provide data on differences in cancer incidence, morbidity, mortality and treatment effects as a function of ethnicity, gender, and age.
|Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7|
|Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:|
|Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Sha, Dan; Lee, Adam M; Shi, Qian et al. (2014) Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res 20:3319-27|
|Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51|
|Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42|
|Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9|
|Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7|
|Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8|
Showing the most recent 10 out of 96 publications